FRA:UDD (Australia)
Â
Business Description

Prescient Therapeutics Ltd
NAICS : 325412
Compare
Compare
Traded in other countries / regions
PTX.AustraliaUDD.GermanyPSTTF.USA Description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.95 | |||||
Piotroski F-Score | 3/9 | |||||
Beneish M-Score | -4.11 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 20.6 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 25.6 | |||||
3-Year Book Growth Rate | -10.3 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | 71.03 | |||||
12-1 Month Momentum % | 281.54 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 17.61 | |||||
Quick Ratio | 17.61 | |||||
Cash Ratio | 15.18 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -27.5 | |||||
ROA % | -26.63 | |||||
ROIC % | -160.89 | |||||
ROC (Joel Greenblatt) % | -542.65 | |||||
ROCE % | -27.41 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4.9 | |||||
Price-to-Tangible-Book | 5.5 | |||||
EV-to-EBIT | -14.91 | |||||
EV-to-EBITDA | -14.92 | |||||
EV-to-FCF | -17.67 | |||||
Price-to-Net-Current-Asset-Value | 5.5 | |||||
Price-to-Net-Cash | 5.5 | |||||
Earnings Yield (Greenblatt) % | -6.71 |